When the liver fails to clear toxic nitrogen waste, it can fuel liver cancer. Damaged urea cycle enzymes cause ammonia to ...

An interdisciplinary multi-center research team led by the LKS Faculty of Medicine (HKUMed) and Faculty of Dentistry at the ...

The FDA is reviewing zanzalintinib combined with atezolizumab for metastatic colorectal cancer, with a PDUFA target date of December 3, 2026. The STELLAR-303 trial showed significant overall survival ...

“Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint ...

Exelixis, Inc. (Nasdaq: EXEL) today announced that its New Drug Application (NDA) for zanzalintinib, in combination with atezolizumab (Tecentriq®), has been accepted for review in the U.S. for the ...

A decline in the incidence of colorectal cancer liver metastases contrasts with survival gains, which are seen in early metachronous disease.

BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...

Patients with liver cancer or cancers that have spread to the liver will soon have an emerging, non-invasive option to consider at Hackensack Meridi ...

Metastasis and disease progression remain the leading causes of mortality in both breast and cervical cancer. These processes ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

A team at UT Southwestern Medical Center this week became the first in Texas and neighboring states to successfully perform a novel procedure to deliver whole-liver chemotherapy to treat metastatic ...

In this analysis, researchers aimed to evaluate the clinicopathologic characteristics, metastatic patterns, and survival outcomes in patients with metastatic prostate cancer and low-volume primary ...